362 related articles for article (PubMed ID: 31127860)
1. Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study.
Uchida H; Kamata M; Mizukawa I; Watanabe A; Agematsu A; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
Br J Dermatol; 2019 Nov; 181(5):1083-1085. PubMed ID: 31127860
[No Abstract] [Full Text] [Related]
2. Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study.
Patruno C; Fabbrocini G; Longo G; Argenziano G; Ferrucci SM; Stingeni L; Peris K; Ortoncelli M; Offidani A; Amoruso GF; Talamonti M; Girolomoni G; Grieco T; Iannone M; Nettis E; Foti C; Rongioletti F; Corazza M; Veneri MD; Napolitano M;
Am J Clin Dermatol; 2021 Jul; 22(4):581-586. PubMed ID: 33725337
[TBL] [Abstract][Full Text] [Related]
3. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series.
Armario-Hita JC; Pereyra-Rodriguez J; Silvestre JF; Ruiz-Villaverde R; Valero A; Izu-Belloso R; Jáuregui-Presa I; Curto-Barredo L; Figueras-Nart I; Herranz-Pinto P; Herraez-Herrera L; Ortiz-de-Frutos FJ; Martinez-Pilar L; Sastre J; Serra-Baldrich E
Br J Dermatol; 2019 Nov; 181(5):1072-1074. PubMed ID: 31021399
[No Abstract] [Full Text] [Related]
4. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
Simpson EL; Paller AS; Siegfried EC; Boguniewicz M; Sher L; Gooderham MJ; Beck LA; Guttman-Yassky E; Pariser D; Blauvelt A; Weisman J; Lockshin B; Hultsch T; Zhang Q; Kamal MA; Davis JD; Akinlade B; Staudinger H; Hamilton JD; Graham NMH; Pirozzi G; Gadkari A; Eckert L; Stahl N; Yancopoulos GD; Ruddy M; Bansal A
JAMA Dermatol; 2020 Jan; 156(1):44-56. PubMed ID: 31693077
[TBL] [Abstract][Full Text] [Related]
5. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Thaçi D; Deleuran M; Blauvelt A; Bissonnette R; de Bruin-Weller M; Hide M; Sher L; Hussain I; Chen Z; Khokhar FA; Beazley B; Ruddy M; Patel N; Graham NMH; Ardeleanu M; Shumel B
Am J Clin Dermatol; 2020 Aug; 21(4):567-577. PubMed ID: 32557382
[TBL] [Abstract][Full Text] [Related]
8. One-year real-world clinical effectiveness, safety, and laboratory safety of dupilumab in Japanese adult patients with atopic dermatitis: A single-center retrospective study.
Uchida H; Kamata M; Kato A; Mizukawa I; Watanabe A; Agematsu A; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
J Am Acad Dermatol; 2021 Feb; 84(2):547-550. PubMed ID: 32479977
[No Abstract] [Full Text] [Related]
9. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study.
Schneeweiss MC; Kim SC; Wyss R; Schneeweiss S; Merola JF
J Am Acad Dermatol; 2021 Feb; 84(2):300-311. PubMed ID: 33038471
[TBL] [Abstract][Full Text] [Related]
10. Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting.
Uchida H; Kamata M; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
J Am Acad Dermatol; 2020 May; 82(5):1247-1249. PubMed ID: 31884090
[No Abstract] [Full Text] [Related]
11. Conjunctivitis in dupilumab clinical trials.
Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.
Faiz S; Giovannelli J; Podevin C; Jachiet M; Bouaziz JD; Reguiai Z; Nosbaum A; Lasek A; Ferrier le Bouedec MC; Du Thanh A; Raison-Peyron N; Tetart F; Duval-Modeste AB; Misery L; Aubin F; Dompmartin A; Morice C; Droitcourt C; Soria A; Arnault JP; Delaunay J; Mahé E; Richard MA; Schoeffler A; Lacour JP; Begon E; Walter-Lepage A; Dillies AS; Rappelle-Duruy S; Barete S; Bellon N; Bénéton N; Valois A; Barbarot S; Sénéchal J; Staumont-Sallé D;
J Am Acad Dermatol; 2019 Jul; 81(1):143-151. PubMed ID: 30825533
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
Liberman P; Shifera AS; Berkenstock M
Cornea; 2020 Jun; 39(6):784-786. PubMed ID: 31985517
[TBL] [Abstract][Full Text] [Related]
14. Prevention of conjunctivitis in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single-centre experience.
Simonetti O; Radi G; Diotallevi F; Molinelli E; Rizzetto G; Offidani A
Clin Exp Dermatol; 2021 Jul; 46(5):939-940. PubMed ID: 33576497
[No Abstract] [Full Text] [Related]
15. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
[TBL] [Abstract][Full Text] [Related]
16. Severe atopic dermatitis: Dupilumab is not just safer, but more efficient.
Giavina-Bianchi M; Rizzo LV; Giavina-Bianchi P
Allergol Immunopathol (Madr); 2020; 48(6):792-797. PubMed ID: 32249095
[TBL] [Abstract][Full Text] [Related]
17. Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis.
Ivert LU; Wahlgren CF; Ivert L; Lundqvist M; Bradley M
Acta Derm Venereol; 2019 Apr; 99(4):375-378. PubMed ID: 30653240
[TBL] [Abstract][Full Text] [Related]
18. Use of dupilumab in patients who are HIV-positive: report of four cases.
Mollanazar NK; Qiu CC; Aldrich JL; Tedaldi E; Valdes-Rodriguez R; Savage KT; Hsu S
Br J Dermatol; 2019 Dec; 181(6):1311-1312. PubMed ID: 31206599
[No Abstract] [Full Text] [Related]
19. Treatment of refractory conjunctivitis associated to dupilumab with topical pimecrolimus applied to the eyelid skin.
Sernicola A; Gattazzo I; Di Staso F; Giordano D; Capalbo A; Persechino F; Scuderi G; Persechino S
Dermatol Ther; 2019 Nov; 32(6):e13134. PubMed ID: 31639238
[TBL] [Abstract][Full Text] [Related]
20. Restoration of sweating disturbance in atopic dermatitis treated with dupilumab.
Mizukawa Y; Sato Y; Ohyama M; Shiohara T
J Dermatol Sci; 2020 Oct; 100(1):79-81. PubMed ID: 32900571
[No Abstract] [Full Text] [Related]
[Next] [New Search]
